REG - Oxford BioDynamics - Director Dealing

Oxford BiodynamicsAnnouncement

20/03/2020 08:10

RNS Number : 9712G
  
Oxford BioDynamics PLC
  
20 March 2020
  
 

 
20 March 2020                                         
 
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Director Dealing
 
Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Christian Hoyer Millar (Chief Executive Officer) has purchased 6,000 Ordinary Shares of 1 pence each at an average price of 49.22 pence per share.
                           
Following this transaction, Christian Hoyer Millar, together with his wife, is interested in 12,364,303 Ordinary Shares, representing approximately 13.36% of the Company's current issued share capital.
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
 



1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name


Christian Hoyer Millar




2


Reason for the notification




a)


Position/status 


Director/PDMR




b)


Initial notification/ Amendment 


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Oxford BioDynamics Plc 




b)


LEI


2138005Y1TK258O5U928




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
Identification code 


Ordinary Shares of 1 pence each
 
ISIN:   GB00BD5H8572




b)


Nature of the transaction


Acquisition of ordinary shares




c)


Price(s) and volume(s)


 



Price(s)


Volume(s)




0.4900


4,000




0.4966


2,000



 
 




d)


Aggregated information
- Aggregated volume
- Price
 


 



Price


Volume




0.4922


6,000



 
 




e)


Date of the transaction


19 March 2020
 




f)


Place of the transaction


Outside a trading venue



 
 
For further details please contact:
 



Oxford BioDynamics Plc 
Christian Hoyer Millar, CEO 
Paul Stockdale, CFO


+44 (0)1865 518910




Shore Capital 
Nominated Adviser and Broker
Stephane Auton
Edward Mansfield


+44 (0)20 7408 4090




FTI Consulting 
Financial Public Relations Adviser
Natalie Garland-Collins


+44 (0)20 3727 1000 



 
Notes for Editors
 
About Oxford BioDynamics Plc
 
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry. 
 
The Company's award-winning, proprietary technology platform, EpiSwitch™, offers non-invasive liquid biopsy readouts to the standards of validated predictive, prognostic and diagnostic patient stratifications, and aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. 
 
In particular, EpiSwitch™ offers non-invasive molecular read-outs with strong links to clinical outcomes, and helps reduce time to market, failure rates and the costs at every stage of drug discovery.  Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
 
In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.
 
The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD".  For more information please visit www.oxfordbiodynamics.com.
 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHFIFFDVDIIFII